The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 mutation. Further studies suggest that PARP inhibitors (PARPi) can also exhibit efficacy in HR-competent cancers, by amplifying the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Med Insights Oncol
Autors principals: Wu, Zhaozhen, Cui, Pengfei, Tao, Haitao, Zhang, Sujie, Ma, Junxun, Liu, Zhefeng, Wang, Jinliang, Qian, Yuanyu, Chen, Shixue, Huang, Ziwei, Zheng, Xuan, Huang, Di, Hu, Yi
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934064/
https://ncbi.nlm.nih.gov/pubmed/33737855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1179554921996288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars